Amgen Ventures and existing backers GV, Heritage Provider Network and Alexandria Venture Investments helped the cancer and IBD drug developer secure fresh funding.
US-based cancer and autoimmune disease drug developer Celsius Therapeutics has raised $83m from investors including internet technology group Alphabet, medical care provider Heritage Provider Network and pharmaceutical firm Amgen.
Healthcare investment firm Casdin Capital led the round, which also featured life sciences-focused real estate investment trust Alexandria Real Estate Equities, Third Rock Ventures, Amplitude Ventures, Catalio Capital, Co-Win Ventures, Fast Track Initiative, Section 32 and unnamed institutional investors.
Alphabet, Amgen and Alexandria participated in the round through GV, Amgen Ventures…
